Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.

PHASE2CompletedINTERVENTIONAL

Enrollment

239

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

February 1, 2022

Study Completion Date

December 7, 2022

Conditions

Influenza

Interventions

BIOLOGICAL

OVX836-003

One single administration intramuscularly at Day 1.

BIOLOGICAL

Saline solution

One single administration intramuscularly at Day 1.

Trial Locations (1)

Centre for Vaccinology (CEVAC), Ghent